AstraZeneca gets USFDA nod for Imfinzi, Imjudo with chemotherapy to treat metastatic non-small cell lung cancer Ruchika Sharma11 Nov 2022 2:30 PM ISTImfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80...
AstraZeneca gets USFDA nod for Imfinzi plus chemotherapy to treat advanced biliary tract cancer Ruchika Sharma5 Sept 2022 1:30 PM ISTBiliary tract cancer is a group of rare and aggressive cancers that occur in the bile ducts and gallbladder.
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: study Dr. Shravani Dali7 July 2022 8:00 PM ISTDurvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer, according to a recent study published in the NEJM Evidence Patients...
AstraZeneca gets CDSCO panel nod to study anticancer drug Durvalumab Dr. Divya Colin3 Jun 2022 7:00 PM ISTNew Delhi: Pharmaceutical major, AstraZeneca has got the go-ahead from the Subject Expert Committee (SEC) of the Central Drugs Standard Control...
AstraZeneca gets CDSCO nod to conduct Phase III CT of antineoplastic FDCs drug Dr. Divya Colin24 May 2022 10:45 AM ISTNew Delhi: Suggesting to increase the number of subjects in clinical trial to 34, from the proposed 24 subjects in India, the Subject Expert Committee...
Labcorp gets CDSCO nod to conduct a study on anticancer drug Dr. Divya Colin20 March 2022 11:15 AM ISTNew Delhi: In a significant development, Labcorp, a leading global life sciences company, has received approval from the Central Drugs Standard...
Durvalumab Significantly Improves Survival for Patients With Biliary Tract Cancer Compared to Chemotherapy Alone Dr. Kamal Kant Kohli29 Jan 2022 9:00 AM ISTBiliary tract cancer is classified as a rare disease comprised primarily of bile duct and gallbladder cancers.Results from a randomized international...
Withdraw marketing of Durvalumab for metastatic urothelial carcinoma: CDSCO panel tells AstraZeneca Medical Dialogues Team27 July 2021 5:43 PM ISTNew Delhi: In a major setback to AstraZeneca Pharma India Limited., the Subject Expert Committee (SEC) of the Central Drugs Standard Control...
AstraZeneca small cell lung cancer treatment Imfinzi gets nod in China Ruchika Sharma19 July 2021 2:15 PM ISTUK: Pharma major, AstraZeneca, announced that Imfinzi (durvalumab) has been approved in China for the 1st-line treatment of adult patients with...
AstraZeneca voluntarily withdraws antibody Imfinzi indication for bladder cancer in US Ruchika Sharma24 Feb 2021 1:37 PM ISTUK: AstraZeneca has recently announced the voluntary withdrawal of the Imfinzi (durvalumab) indication in the US for previously treated adult patients...
AstraZeneca lung cancer drug Imfinzi gets nod for new dosing regimen in EU, UK Ruchika Sharma18 Jan 2021 10:30 AM ISTNew Delhi: AstraZeneca has recently announced that the company's Imfinzi (durvalumab) has been approved in the European Union and the UK for an...
AstraZeneca halts clinical trials of its drugs to treat lung cancer Pooja Bhatia Bhatia10 Oct 2015 12:45 PM ISTAfter reports of developing lung cancers in some patients, AstraZeneca has temporarily halted two clinical trials combining experimental drugs to...
